The pattern of DNAM-1, TIGIT and TACTILE co-expression in AML patients may constitute a biomarker for checkpoint blockade directed at inhibitory receptors that interact with CD112 and CD155 proteins. Here, PVR is linked to acute myeloid leukemia.